Table 2 Disease activity measures at baseline and the first follow-up observation
Outcome | Total (n = 1753) | Male (n = 1343) | Female (n = 410) | p-value |
|---|---|---|---|---|
Baseline | ||||
BASDAI, mean (SD) | 5.98 (1.99) | 5.91 (1.95) | 6.24 (2.08) | 0.002 |
ASDAS, mean (SD) | 3.6 (1.07) | 3.62 (1.05) | 3.55 (1.12) | 0.259 |
PGA, mean (SD) | 6.33 (2.1) | 6.29 (2.08) | 6.48 (2.17) | 0.110 |
CRP, mg/dL, mean (SD) | 2.14 (2.89) | 2.23 (2.92) | 1.85 (2.78) | < 0.001 |
Follow-up | ||||
BASDAI, mean (SD) | 2.7 (2.09) | 2.6 (2.04) | 3.02 (2.22) | 0.001 |
ASDAS, mean (SD) | 1.68 (1.02) | 1.67 (1.01) | 1.69 (1.04) | 0.966 |
PGA, mean (SD) | 3.2 (2.25) | 3.09 (2.2) | 3.55 (2.37) | < 0.001 |
CRP, mg/dL, mean (SD) | 0.54 (1.54) | 0.58 (1.61) | 0.42 (1.27) | < 0.001 |